Back to search

National and Kapodistrian University of Athens

Ο ρόλος των αντιαποπτωτικών παραγόντων IGF-1, TGF-β, IL-6 στη θεραπεία των ηπατικών μεταστάσεων

Abstract

dc:description

The liver is the organ that many primary tumors induse metastases. Despite the progress in chemotherapy the prognosis in metastatic liver disease remains poor.Recently in an effort to modify the effect of chemotherapy several biological factors that the implicated in the processes of metastases are investigated. Somatostatin an its analogue octreotide in its slow-release form (LAR) along with graded dose of dexamethasone has been tested in the treatment of metastatic diseaseas an anti-survival factor ASF.It was shown to exert antitumour activity through indirect effects on the microenvironment of metastatic cells in the liver.This effect was achieved by the suppression of the following growth factors IGF-1, TGF-b, IL- 6 that are implicated in metastasis excerting an anti-apoptotic effect. Somatostatin agonists have a preferable toxicity profile a convenient dosage schedules and can implemented in the outpatient treatment.The aim: To clarify the role of the antiapoptotic factors IGF-1, TGF-b, IL-6, in metastatic liver disease. To investgate the effectiveness of LAR with dexamethasone (ASF treatment) as adjuvant to classical chemotherapy.Μethods: From the outpatient Department of Medical Oncology at Laikon hospital 101 patient that had metastatic disease in the liver mainly from colorectal cancer and were treated with chemotherapy were enrolled in the study. The first group of 48 received the chemotherapy regimen plus LAR and dexamethasone in the ASF treatment setting. The second group of 53 patient received only chemotherapy . The IGF-1, TGF-b and IL-6levels were measured just before treatment and every three months during treatment with standard immunoassay methods - enzyme-linked immunosorbent assay (ELISA) using a double antibody (a type of sandwich). In addition during treatment in the two groups of patients quality of life,disease free survival,clinical responseand overal survival were estimated and compared. Results: There were 101 patients with metastatic liver disease 59 (58.4%) male and 42 (41.6%) women.Mean age 61 years ,33 (32.7 %) had a single metastasis, 24 (23.8%) had two, 44 (43.6%) had more than three metastases.Performance status was 2 for 61 (60.4%) and 3 for 40 (39.6 %) patients . The patients that received chemotherapy and ASF treatment showed significant decreases in TGF-b levels(mean reduction was 134,3 mg / dl ) as compared to the chemotherapy group (p-value <0.001).Similary decline at the IGF-1 levels was documented in the ASF group (levels average decrease was 22,9 ng / ml with p-value <0.001)Patients at the ASF group showed a better survival with a prpbability of death at 37,5% as compared to 49.7% of the chemotherapy group (p-value <0.001). Women at the ASF group had better survival with a chance of death at 29.6% as compared to 54.2% (p-value = 0.024)of the chemotherapy.A Tendency for better survival was documented in patients whose TGF-b levels were dramatically reduced as compared to those whose TGF-b levels remained highly after treatment.Patients with TGF-b levels> 402 ng / ml 51 times greater chance of dying(p-value = 0.010). ASF treatment for 3 or 6 months was associated with reduced odds of deterioration by 57% and 71% respectively as compared to chemotherapy group (p-value = 0.002). Patients on ASF treatment had a 10 times better chance of responding to chemotherapy by taking into consideration the number of metastatic lesions and the drop of IGF-1 levels (p-value <0.001). Patients on ASF treatment had by 83% less chance of performance status deterioration as compared to chemotherapy group taking into consideration patients age, number of liver metastases and initial levels of TGF-b (p-value = 0.002)Conclusions: The present study demonstrated that the addition of LAR plus dexamethasone to chemotherapy as an ASF had a favourable effect on the group by improving PS and quality of life .It also increased progression free survival and had a small effect on overall survival.These results in conjunction with the excellent toxity profile of the two drugs warrands furter evalutation of those complexes in clinical trials.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Halikias, Spyridon
  • Χαλικιάς, Σπυρίδων

Subjects

dc:subject × 17

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38643

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Halikias, Spyridon; Χαλικιάς, Σπυρίδων. Ο ρόλος των αντιαποπτωτικών παραγόντων IGF-1, TGF-β, IL-6 στη θεραπεία των ηπατικών μεταστάσεων. National and Kapodistrian University of Athens, 2013. http://hdl.handle.net/10442/hedi/38643